• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
NetScientific acquires 100% control of portfolio company ProAxsis Limited
Share
Announcements, News

NetScientific acquires 100% control of portfolio company ProAxsis Limited

October 16, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces a significant change to its investor base.

Netscientific, who previously held a 56.4% equity share of ProAxsis, have taken full control of the company through acquisition of all the remaining shares via the execution of private purchasing agreements with QUBIS Limited, the commercialisation arm of Queen’s University Belfast and the two company co-founders.  In parallel, the key patent associated with the ProteaseTag® technology has been assigned to ProAxsis.

Dr. Ilian Iliev, Chief Executive Officer of NetScientific Plc said: “In line with the Group’s Strategic Review and stated plans, ProAxsis is an example of the strong commercialisation potential of spin out companies from UK Universities such as Queen’s University Belfast. This provides an early investment realisation opportunity for the company’s two co-founders, Professor Lorraine Martin and Professor Brian Walker, while allowing the company to continue and accelerate its growth. In line with NetScientific’s pro-active management, increasing our stake in ProAxsis via these agreements will enable us to provide the necessary support required to maximise the company’s value and help the company capture synergies within our broader ecosystem in this growing sector. We are delighted that David Moore, the University’s Head of Spin Outs and Investments at QUBIS, has agreed to remain on the ProAxsis board of directors for the foreseeable future.”

 

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

For more information, please visit the website at: www.ProAxsis.com

October 16, 2020

Related News

Other posts that you should not miss.
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the …

Read More
June 19, 2017
Posted by Webmaster
Announcements, Neutrophil Elastase Immunoassay, News

ProAxsis Limited appoints distributor for key North America region

November 19, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory …

Read More
November 19, 2020
Posted by David Ribeiro
News

ProAxsis announces commercial team expansion

June 21, 2021
-
Posted by David Ribeiro

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce …

Read More
June 21, 2021
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis Limited appoints distributor for key North America region
NEXT POST →
ProAxsis accelerates work on inflammatory biomarkers associated with COVID-19
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
NetScientific acquires 100% control of portfolio company ProAxsis Limited - ProAxsis